Injection paradigm for administration of botulinum toxins
Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
1. A method for treating or reducing the occurrence of a headache in a patient with chronic migraine headaches, the method comprising:
local administration of a botulinum neurotoxin to 31 fixed injection sites across seven head and neck muscles, and optionally up to 8 additional injection sites into three specific muscles, wherein these three muscles are subset of the seven head and neck muscles,
to thereby treat or reduce the occurrence of chronic migraine headache in the patient.
2. The method of claim 1 , wherein the 31 fixed injection sites across the seven head and neck muscles comprise four injection sites in the frontalis; two injection sites in the corrugator; one injection site in the procerus; six injection sites in the occipitalis; eight injection sites in the temporalis; six injection sites in the trapezius and four injection sites in the paraspinal muscles.
3. The method of claim 1 , wherein the 8 additional injection sites into three specific muscles comprise two injection sites in the occipitalis; two injection sites in the temporalis; and four injection sites in the trapezius.
4. The method of claim 1 , wherein the botulinum neurotoxin is serotype A.
5. The method of claim 4 , wherein the botulinum neurotoxin type A is onabotulinumtoxinA.
6. The method of claim 4 , wherein the total amount of botulinum toxin type A administered is from about 155 units to about 195 units of onabotulinumtoxinA.
7. The method of claim 4 , wherein the total amount of botulinum toxin type A administered to the 31 injection sites is about 155 units of onabotulinumtoxinA.
8. The method of claim 1 , wherein the botulinum toxin is a pure botulinum toxin.
9. The method of claim 8 , wherein the botulinum neurotoxin type A is incobotulinumtoxinA.
10. The method of claim 8 , wherein the total amount of botulinum toxin type A administered is from about 155 units to about 195 units of incobotulinumtoxinA.
11. The method of claim 8 , wherein the total amount of botulinum toxin type A administered to the 31 injection sites is about 155 units of incobotulinumtoxinA.
12. The method of claim 4 , wherein the botulinum neurotoxin type A is abobotulinumtoxinA.
13. The method of claim 4 , wherein the total amount of botulinum toxin type A administered is from about 310 units to about 975 units of abobotulinumtoxinA.
14. The method of claim 4 , wherein the total amount of botulinum toxin type A administered to the 31 injection sites is about 310 units of abobotulinumtoxinA.
15. The method of claim 1 , wherein the botulinum neurotoxin is serotype B.
16. The method of claim 1 wherein the botulinum neurotoxin is type E.
17. The method of claim 1 , wherein the headache is decreased for at least 12 weeks.
18. The method of claim 1 , wherein the administration is by injection.
19. The method of claim 1 , wherein the administration is by subcutaneous injection.
20. The method of claim 1 , wherein the administration is by intramuscular injection.